Lactose 1g/5ml oral solution
Requires a prescription from a doctor or prescriber
A disaccharide of glucose and galactose in human and cow milk.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Lactose
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Oral liquids
(1)Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(5)
Irritable bowel syndrome in adults: diagnosis and management (CG61)
Coeliac disease: recognition, assessment and management (NG20)
Irritable bowel syndrome in adults (QS114)
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 34 · Randomised trials: 7 · 1979–2026
Showing the 50 most relevant studies, sorted by most relevant.
Sophia Oak, R. Jha
Critical Reviews in Food Science and Nutrition, 2019
Christian Løvold Storhaug, Svein Kjetil Fosse, L. Fadnes
The lancet. Gastroenterology & hepatology, 2017
B. Misselwitz, M. Butter, K. Verbeke, et al.
Gut, 2019
P. Dekker, Damiet J P C Koenders, M. Bruins
Nutrients, 2019
A. Szilagyi, Norma Ishayek
Nutrients, 2018
J. Osorio, J. Lohakare, M. Bionaz
Physiological genomics, 2016
A. Costa, N. Lopez-Villalobos, N. Sneddon, et al.
Journal of dairy science, 2019
Magda Corgneau, J. Scher, Léa Ritié‐Pertusa, et al.
Critical Reviews in Food Science and Nutrition, 2017
Miketinas DC, Patterson MA, Thyne VK, et al.
2026
Preterm human milk (HM) is a major source of carbohydrates (CHOs), primarily lactose, which contribute to energy intake and support growth and neurodevelopment. This systematic review and meta-analyses quantified total CHO, lactose, and energy content in preterm HM. EBSCO (Health Source-Nursing/Academic Edition and MEDLINE with Full Text), PubMed, and Scopus were searched through July 2023 for studies reporting nutrient composition in preterm HM (2 and publication bias using Begg's rank correlation test. Repeated measures were aggregated. Of 884 identified articles, 53 studies reported total CHO, lactose, and energy. Mean (95% confidence interval) total CHO was 6.74 (6.41, 7.07) g/100 mL with the lowest concentration in colostrum [6.30 (6.13, 6.48) g/100 mL]. Total CHO was similar for transition [6.83 (6.60, 7.06) g/100 mL] and mature [6.80 (6.45, 7.14) g/100 mL] HM. Lactose followed a comparable pattern, with an overall mean of 6.33 (6.02, 6.64) g/100 mL. Mean energy content was 68.13 (65.92, 70.33) kcal/100 mL; colostrum had the lowest, whereas transition and mature were similar. Stratified analyses by analytical method and milk type were also conducted. This systematic review provides updated pooled estimates of total CHO and lactose concentrations and energy in preterm HM and highlights substantial variability related to study design, analytical methods, and data reporting. This trial was registered at the International Prospective Register of Systematic Reviews (https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=445191) as CRD42023445191.
Abstract licence: CC BY
Almalki AH, Apekey T, Ranawana V
2026
ContextLactose intolerance (LI) is a common condition characterized by lactase deficiency and impaired digestion of lactose. Dairy avoidance among affected individuals can reduce intakes of calcium, vitamin D, and phosphorus, with potential implications for bone health. Therefore, this review aimed to assess the effects of LI on calcium, vitamin D and phosphorus status, as well as related bone health in adults.ObjectiveThis systematic review synthesizes evidence regarding implications for bone health reported in observational studies on calcium, vitamin D, and phosphorus status in adults with LI and dairy avoidance.Data sourcesPubMed, Web of Science, Scopus, and CINAHL were searched for studies from 1980 to 2024. The strategy followed the population-intervention-comparison-outcome framework and used MeSH terms with Boolean operators. Eligible designs were observational; most were cross-sectional studies and included adults (aged ≥18 years) with LI.Data extractionData were extracted on study characteristics, population demographics, diagnostic methods, assessment of micronutrient status, and bone outcomes. Risk of bias was assessed using the Newcastle-Ottawa Scale, adapted for cross-sectional designs.Data analysisA narrative synthesis following the Synthesis Without Meta-analysis (SWiM) guidelines was used to compare nutritional and bone outcomes between lactose-intolerant and lactose-tolerant groups. Thirteen studies were included. Overall, study quality was mostly good or satisfactory, with few studies rated as unsatisfactory or fair. For serum calcium and phosphorus, studies generally did not demonstrate differences by LI status. Evidence on vitamin D was limited to 3 studies with heterogenous results; therefore, we cannot conclude that vitamin D status is unaffected. Conversely, LI was generally associated with significantly reduced calcium intake. Bone outcomes were inconsistent.ConclusionsGiven inconsistent evidence across studies, chronically low calcium intake in LI may be associated with, but not definitively causal for, adverse bone outcomes. Our findings support ensuring sufficient calcium intake and highlighting the need for prospective studies.Systematic review registrationPROSPERO registration No. [CRD42024607063].
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Proteins and enzymes this drug interacts with in the body
In the nucleus: acts as a pre-mRNA splicing factor. Involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells. Together with TRIM16, coordinates the recognition of membrane damage with mobilization of the core autophagy regulators ATG16L1 and BECN1 in response to damaged endomembranes
Involved compounds
Involved compounds
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Lactose
Additional database identifiers
Drugs Product Database (DPD)
6757
ChemSpider
389820
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6563
GenAtlas
LGALS3
GeneCards
LGALS3
GenBank Gene Database
M57710
GenBank Protein Database
179531
UniProt Accession
LEG3_HUMAN
GenBank Gene Database
D01045
GenBank Protein Database
216784
UniProt Accession
NANH_MICVI
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4298
GeneCards
GLB1
UniProt Accession
BGAL_HUMAN
GenBank Gene Database
J01636
GenBank Protein Database
146577
UniProt Accession
BGAL_ECOLI
HUGO Gene Nomenclature Committee (HGNC)
HGNC:23671
GeneCards
GLT6D1
UniProt Accession
GL6D1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:24867
GenAtlas
GLTP
GeneCards
GLTP
GenBank Gene Database
AF209704
GenBank Protein Database
6959686
UniProt Accession
GLTP_HUMAN
UniProt Accession
Q7SI98_STROI
GenBank Gene Database
M64551
UniProt Accession
XYNA_STRLI
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72